GLP-1 Drugs Clear Psoriasis Within 2 Days as Studies Point to Direct Anti-Inflammatory Effects
Updated
Updated · Medscape · Jul 12
GLP-1 Drugs Clear Psoriasis Within 2 Days as Studies Point to Direct Anti-Inflammatory Effects
2 articles · Updated · Medscape · Jul 12
Summary
Psoriasis plaques in some patients starting GLP-1 therapy began fading within 2 days, a speed dermatologists say is too fast to be explained by weight loss alone.
Genetic and clinical evidence increasingly points to a direct anti-inflammatory effect: a recent analysis linked more active GLP-1 receptors to lower psoriasis and psoriatic arthritis risk even after accounting for body fat.
Early data also extend beyond psoriasis. Observational studies suggest benefits in hidradenitis suppurativa, mixed signals in atopic dermatitis, and several studies indicate faster wound healing.
A trial reported earlier this year found tirzepatide plus ixekizumab beat ixekizumab alone in overweight or obese adults with psoriasis, reinforcing interest in GLP-1s as skin treatments.
Researchers are now pushing for head-to-head trials of GLP-1s alone for skin disease, with psoriasis leading and hidradenitis suppurativa viewed as another key target.
GLP-1 receptor agonists (GLP-1RAs), first used for diabetes and weight management, are now showing rapid and significant improvements in psoriasis, often clearing plaques within days. This effect appears to work independently of weight loss, suggesting a direct anti-inflammatory action. Recent studies and case reports highlight their potential, with patients experiencing notable reductions in psoriasis severity. These findings point to a new and promising direction for psoriasis treatment, as GLP-1RAs may offer benefits beyond their original use, providing hope for better management of this chronic skin condition.